@article{3220348,
    title = "Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations",
    author = "Tausch, E. and Ljungström, V. and Agathangelidis, A. and Zapatka, M. and Scarfò, L. and Jebaraj, B.M.C. and Yosifov, D.Y. and Müller, A. and Munugalavadla, V. and Degenhardt, J.D. and Ghia, P. and Rosenquist, R. and Stilgenbauer, S.",
    journal = "Blood advances",
    year = "2022",
    volume = "139",
    number = "22",
    pages = "3340-3344",
    publisher = "NLM (Medline)",
    doi = "10.1182/blood.2021014550",
    keywords = "idelalisib;  purine derivative;  quinazolinone derivative, drug resistance;  genetics;  MAPK signaling;  mutation;  tumor cell line;  upregulation, Cell Line, Tumor;  Drug Resistance, Neoplasm;  MAP Kinase Signaling System;  Mutation;  Purines;  Quinazolinones;  Up-Regulation"
}